de Primecap Management Edwards Lifesciences EW Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 308 M | Vender |
3,408,291
-14,500
| -0.4% | -USD 1.21 M | 0.18% | 97 |
|
|
2026
Q1 | USD 274 M | Comprar |
3,422,791
+4,000
| +0.1% | +USD 330 k | 0.22% | 89 |
|
|
2025
Q4 | USD 291 M | Vender |
3,418,791
-104,500
| -3% | -USD 8.58 M | 0.22% | 90 |
|
|
2025
Q3 | USD 274 M | Comprar |
3,523,291
+76,400
| +2% | +USD 5.97 M | 0.21% | 91 |
|
|
2025
Q2 | USD 270 M | Comprar |
3,446,891
+1,147,291
| +50% | +USD 85.6 M | 0.21% | 87 |
|
|
2025
Q1 | USD 167 M | Comprar |
2,299,600
+256,100
| +13% | +USD 18.3 M | 0.14% | 108 |
|
|
2024
Q4 | USD 151 M | Comprar |
2,043,500
+258,800
| +15% | +USD 18.1 M | 0.12% | 118 |
|
|
2024
Q3 | USD 118 M | Vender |
1,784,700
-26,300
| -1% | -USD 1.91 M | 0.09% | 130 |
|
|
2024
Q2 | USD 167 M | Vender |
1,811,000
-90,000
| -5% | -USD 7.97 M | 0.12% | 108 |
|
|
2024
Q1 | USD 182 M | Mantener |
1,901,000
| – | – | 0.14% | 101 |
|
|
2023
Q4 | USD 145 M | Vender |
1,901,000
-35,000
| -2% | -USD 2.44 M | 0.11% | 112 |
|
|
2023
Q3 | USD 134 M | Mantener |
1,936,000
| – | – | 0.11% | 114 |
|
|
2023
Q2 | USD 183 M | Mantener |
1,936,000
| – | – | 0.15% | 105 |
|
|
2023
Q1 | USD 160 M | Vender |
1,936,000
-30,000
| -2% | -USD 2.36 M | 0.14% | 108 |
|
|
2022
Q4 | USD 147 M | Vender |
1,966,000
-90,300
| -4% | -USD 6.96 M | 0.13% | 112 |
|
|
2022
Q3 | USD 170 M | Mantener |
2,056,300
| – | – | 0.16% | 105 |
|
|
2022
Q2 | USD 196 M | Vender |
2,056,300
-59,200
| -3% | -USD 6.13 M | 0.17% | 96 |
|
|
2022
Q1 | USD 249 M | Vender |
2,115,500
-72,800
| -3% | -USD 8.17 M | 0.19% | 97 |
|
|
2021
Q4 | USD 283 M | Vender |
2,188,300
-84,100
| -4% | -USD 9.8 M | 0.2% | 97 |
|
|
2021
Q3 | USD 257 M | Vender |
2,272,400
-153,100
| -6% | -USD 17.5 M | 0.18% | 102 |
|
|
2021
Q2 | USD 251 M | Mantener |
2,425,500
| – | – | 0.17% | 106 |
|
|
2021
Q1 | USD 203 M | Comprar |
2,425,500
+105,000
| +5% | +USD 8.88 M | 0.14% | 116 |
|
|
2020
Q4 | USD 212 M | Mantener |
2,320,500
| – | – | 0.16% | 110 |
|
|
2020
Q3 | USD 185 M | Mantener |
2,320,500
| – | – | 0.15% | 111 |
|
|
2020
Q2 | USD 160 M | Mantener |
2,320,500
| – | – | 0.14% | 118 |
|
|
2020
Q1 | USD 146 M | Comprar |
2,320,500
+715,500
| +45% | +USD 51.6 M | 0.14% | 113 |
|
|
2019
Q4 | USD 125 M | Mantener |
1,605,000
| – | – | 0.09% | 132 |
|
|
2019
Q3 | USD 118 M | Mantener |
1,605,000
| – | – | 0.09% | 135 |
|
|
2019
Q2 | USD 98.8 M | Mantener |
1,605,000
| – | – | 0.07% | 145 |
|
|
2019
Q1 | USD 102 M | Mantener |
1,605,000
| – | – | 0.08% | 145 |
|
|
2018
Q4 | USD 81.9 M | Mantener |
1,605,000
| – | – | 0.07% | 147 |
|
|
2018
Q3 | USD 93.1 M | Mantener |
1,605,000
| – | – | 0.06% | 148 |
|
|
2018
Q2 | USD 77.9 M | Mantener |
1,605,000
| – | – | 0.06% | 149 |
|
|
2018
Q1 | USD 74.6 M | Comprar |
1,605,000
+105,000
| +7% | +USD 4.56 M | 0.06% | 153 |
|
|
2017
Q4 | USD 56.4 M | Vender |
1,500,000
-76,200
| -5% | -USD 2.8 M | 0.04% | 167 |
|
|
2017
Q3 | USD 57.4 M | Vender |
1,576,200
-103,800
| -6% | -USD 3.96 M | 0.05% | 167 |
|
|
2017
Q2 | USD 66.2 M | Mantener |
1,680,000
| – | – | 0.06% | 162 |
|
|
2017
Q1 | USD 52.7 M | Mantener |
1,680,000
| – | – | 0.05% | 163 |
|
|
2016
Q4 | USD 52.5 M | Mantener |
1,680,000
| – | – | 0.05% | 156 |
|
|
2016
Q3 | USD 67.5 M | Mantener |
1,680,000
| – | – | 0.07% | 147 |
|
|
2016
Q2 | USD 55.8 M | Mantener |
1,680,000
| – | – | 0.06% | 156 |
|
|
2016
Q1 | USD 49.4 M | Mantener |
1,680,000
| – | – | 0.05% | 162 |
|
|
2015
Q4 | USD 44.2 M | Mantener |
1,680,000
| – | – | 0.05% | 174 |
|
|
2015
Q3 | USD 39.8 M | Mantener |
1,680,000
| – | – | 0.04% | 178 |
|
|
2015
Q2 | USD 39.9 M | Mantener |
1,680,000
| – | – | 0.04% | 181 |
|
|
2015
Q1 | USD 39.9 M | Mantener |
1,680,000
| – | – | 0.04% | 179 |
|
|
2014
Q4 | USD 35.7 M | Mantener |
1,680,000
| – | – | 0.04% | 183 |
|
|
2014
Q3 | USD 28.6 M | Mantener |
1,680,000
| – | – | 0.03% | 185 |
|
|
2014
Q2 | USD 24 M | Mantener |
1,680,000
| – | – | 0.03% | 185 |
|
|
2014
Q1 | USD 20.8 M | Mantener |
1,680,000
| – | – | 0.02% | 189 |
|
|
2013
Q4 | USD 18.4 M | Mantener |
1,680,000
| – | – | 0.02% | 196 |
|
|
2013
Q3 | USD 19.5 M | Mantener |
1,680,000
| – | – | 0.03% | 193 |
|
|
2013
Q2 | USD 18.8 M | Comprar |
+1,680,000
| Nuevas | +USD 19.9 M | 0.03% | 190 |
|
Otros fondos que tienen EW en su cartera
Posición de Primecap Management en EW: resumen de T2 2026
Primecap Management redujo su participación en Edwards Lifesciences (EW) en 0.42% durante T2 2026, al vender acciones por un valor estimado de USD 1.21 M, y conservó 3,408,291 acciones valuadas en USD 308 M. La posición representa 0.18% de la cartera y ocupa el puesto #97.
Primecap Management reportó por primera vez una posición en EW en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 1,339 fondos que sigue Wall St. Rank mantienen una posición en EW.
- Al cierre de T2 2026, Primecap Management tenía 3,408,291 acciones de Edwards Lifesciences con un valor de USD 308 M.
- Primecap Management vendió 14,500 acciones de Edwards Lifesciences en T2 2026, por un valor estimado de USD 1.21 M.
- Edwards Lifesciences representó 0.18% de la cartera de Primecap Management en T2 2026 y fue su posición número 97.
- Primecap Management reportó por primera vez una posición en Edwards Lifesciences en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 1,339 fondos que sigue Wall St. Rank tenían Edwards Lifesciences en cartera.
Según el Informe 13F de Primecap Management correspondiente a T2 2026, presentado el 14 ago 2026.